Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. intestinal tract
Show results for
Products
Services
Applications

Companies

News
Articles
Books
Downloads

Refine by
Date

  • Older

Intestinal Tract Articles & Analysis

19 news found

Infection Control Resources to Safeguard Patients from Vancomycin-Resistant Enterococci and Other Pathogens

Infection Control Resources to Safeguard Patients from Vancomycin-Resistant Enterococci and Other Pathogens

The New York State Department of Health (NYSDOH) describes enterococci as part of the normal flora in the intestinal tract and also a common cause of nosocomial infections. The bacteria can also often found in the natural environment, in soil and water. ...

ByCochrane & Associates, LLC


Creative Proteomics Metabolomics Expands Service Offering with the Launch of Gut Microbiota Metabolomics Solution

Creative Proteomics Metabolomics Expands Service Offering with the Launch of Gut Microbiota Metabolomics Solution

Gut flora refers to the microorganisms living in the human intestinal tract, such as Bifidobacteria, Lactobacilli, etc. Over 10 trillion parasitic bacteria are present within the human intestinal tract. ...

ByCreative Proteomics


Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease

Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease

It is specifically designed to preferentially block CB1 receptors in peripheral tissues such as the kidneys, gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs. ...

ByInversago Pharma


Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease

Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease

It is specifically designed to preferentially block CB1 receptors in peripheral tissues such as the kidneys, gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs. ...

ByInversago Pharma


Inversago Pharma presents data on INV-202 in Diabetic Nephropathy at the ERA 2022 Congress

Inversago Pharma presents data on INV-202 in Diabetic Nephropathy at the ERA 2022 Congress

It is specifically designed to preferentially interact with peripheral CB1 receptors located in the kidneys, gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs, thus aiming at a safe and effective therapeutic approach without the known liabilities of centrally-acting CB1 blockers. ...

ByInversago Pharma


Fecal biomarkers - diagnostic possibilities in the context of inflammatory bowel disease

Fecal biomarkers - diagnostic possibilities in the context of inflammatory bowel disease

Here, it accounts for up to 60% of the cytosolic protein content. During intestinal inflammation, neutrophilic granulocytes migrate from the bloodstream into the intestinal lumen (Roseth et al., 1997). ...

ByImmundiagnostik AG


Immundiagnostik`s Colorectal Cancer Screening Portfolio

Immundiagnostik`s Colorectal Cancer Screening Portfolio

The haemoglobin-haptoglobin complex is more stable during intestinal transit than unbound haemoglobin and therefore also indicates bleeding adenomas and carcinomas of the upper intestinal tract. ...

ByImmundiagnostik AG


Creative Enzymes Launches a Weight Control Formula to Improve Intestinal Health

Creative Enzymes Launches a Weight Control Formula to Improve Intestinal Health

The subjects of the experiment were several twin sisters and mice. The intestinal flora of the fat girls made the mice fat, and the intestinal flora of the thin girls made the mice thin. ...

ByCreative Enzymes


Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties

Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties

The platform consists of investigational drug technologies designed to potentially rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract. For more information on Rebiotix and its pipeline of human microbiome-directed therapies for diverse disease states, visit www.rebiotix.com, or connect with ...

ByRebiotix Inc., a Ferring Company


Ferring to Present Award-Winning, Landmark Research for Investigational Microbiota-Based Live Biotherapeutic RBX2660 at IDWeek 2021

Ferring to Present Award-Winning, Landmark Research for Investigational Microbiota-Based Live Biotherapeutic RBX2660 at IDWeek 2021

The platform consists of investigational drug technologies designed to potentially rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract. For more information on Rebiotix and its pipeline of human microbiome-directed therapies for diverse disease states. ...

ByRebiotix Inc., a Ferring Company


Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)

Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)

About Inflammatory Bowel Disease Inflammatory bowel disease (IBD) is a debilitating, life-long condition that results from chronic inflammation of the intestinal tract. The most common forms of IBD are ulcerative colitis and Crohn's disease, which are both characterized by diarrhea, rectal bleeding, abdominal pain, fatigue and weight loss that can lead to ...

ByVedanta Biosciences, Inc


Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection

Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection

The platform consists of investigational drug technologies designed to potentially rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal ...

ByRebiotix Inc., a Ferring Company


Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health

Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health

The new agreement builds on the existing collaboration between Ferring and MyBiotics, initiated in 2017, which has already successfully piloted technologies intended to stabilise selected bacterial species critical to the health of the female reproductive tract using MyBiotics’ MyCrobe technology. “We are proud to be undertaking this collaboration, as it is a ...

ByRebiotix Inc., a Ferring Company


Ferring Pharmaceuticals to Present New Microbiome Research Data at IDWeek 2020

Ferring Pharmaceuticals to Present New Microbiome Research Data at IDWeek 2020

” Recurrent C. difficile infection (rCDI) is a serious, sometimes deadly disease that impacts patients across the globe. Often associated with intestinal microbiome disruption, or “dysbiosis,” rCDI treatment standard of care is currently antibiotics, which is also a predominant risk factor for recurrence. ...

ByRebiotix Inc., a Ferring Company


Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660

Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660

The microbiome aids in the maintenance and development of the immune system, metabolism, and other functions essential to human life.8 The gastrointestinal tract houses the most dense and complex population of microbiota, which has an incredible influence over daily health – from aiding in food digestion to fighting disease. ...

ByRebiotix Inc., a Ferring Company


Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660

Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660

The platform consists of investigational drug technologies designed to potentially rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract. About Ferring Pharmaceuticals Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world ...

ByRebiotix Inc., a Ferring Company


New study:  Nine out of ten U.S. infants experience gut microbiome deficiency

New study: Nine out of ten U.S. infants experience gut microbiome deficiency

” B. infantis had been widely considered one of the most prevalent bacteria in the GI tracts of infants, accordingly its absence from such a wide swath of outwardly healthy infants is surprising. ...

ByEvolve BioSystems, Inc.


Rebiotix, Inc. and Karolinska Institutet Expand Partnership to Shape the Future of Microbiome Research

Rebiotix, Inc. and Karolinska Institutet Expand Partnership to Shape the Future of Microbiome Research

The platform consists of investigational drug technologies designed to potentially rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract. About Ferring Pharmaceuticals Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world ...

ByRebiotix Inc., a Ferring Company


Mid-Atlantic Infection Control Professionals Help Healthcare Facilities Battle VRE

Mid-Atlantic Infection Control Professionals Help Healthcare Facilities Battle VRE

These bacteria, that are often present in the human intestines and female genital tract, are also often found in the environment. ...

ByCochrane & Associates, LLC

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT